Bionoia Where life meets thought ⌕
Back to Journal
Journal › Mucosa
Discovery

Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease

Hypothesis
Read original paper
Editor's note
GLP-2 analogues offer a rare opportunity to regenerate intestinal tissue rather than simply manage nutrient losses in short bowel syndrome—a shift from decades of supportive-only care. This minireview synthesizes emerging evidence that newer agents like glepaglutide extend benefits beyond malabsorption to barrier restoration and IBD, though the field remains early-stage with safety data still accumulating. Gastroenterologists managing intestinal failure and surgeons treating short bowel patients should reassess whether pharmaceutical adaptation now rivals surgical intervention.

Source: openalex · Philippe Attieh, Dana Dabboussi, Wael Meraabi, Karam Karam, Rose Raymond Al Bacha · World Journal of Gastrointestinal Pharmacology and Therapeutics · 2026-05-27

URL: https://doi.org/10.4292/wjgpt.v17.i2.118861

AI rationale (4/5, tier: emerging): GLP-2 directly enhances intestinal barrier integrity and mucosal growth via named mechanisms (cAMP, IGF-1), core to mucosa corpus.

Short bowel syndrome represents a severe form of intestinal failure characterized by malabsorption and dependence on parenteral nutrition (PN). Advances in gut hormone research have positioned glucagon-like peptide-2 (GLP-2) and its analogues as key pharmacologic agents promoting intestinal adaptation and reducing PN dependence. This minireview summarizes current evidence on the mechanisms, clinical efficacy, and expanding therapeutic applications of GLP-2 analogues, with emphasis on emerging agents such as glepaglutide and their safety profiles. GLP-2, a 33-amino acid peptide secreted by enteroendocrine L cells, enhances mucosal growth, nutrient absorption, and intestinal barrier integrity through activation of cyclic adenosine monophosphate-dependent and insulin-like growth factor-1-mediated pathways. Clinical trials have demonstrated that teduglutide and newer long-acting analogues such as glepaglutide significantly increase plasma citrulline levels, reduce fecal output, and decrease PN requirements while improving hepatic function and quality of life. Additionally, preclinical and clinical data support GLP-2’s anti-inflammatory effects in inflammatory bowel disease and its potential to mitigate intestinal failure-associated liver disease. Although current evidence indicates low neoplastic risk, long-term safety monitoring remains essential. GLP-2 analogues represent a paradigm shift in short bowel syndrome management, transforming care from supportive nutrition to regenerative therapy. Ongoing studies exploring novel formulations, broader indications, and precision medicine approaches will further refine their clinical integration and maximize therapeutic benefit.

Related articles in this corpus

Parallel
Bile acids as signaling molecules — FXR and TGR5
Both articles examine distinct molecular signaling pathways (bile acid receptors vs. GLP-2) that independently promote intestinal epithelial regeneration and barrier function in gastrointestinal disease.
Parallel
The glycocalyx and heparan sulfate / syndecan-1
Both articles address intestinal barrier dysfunction and therapeutic interventions in gastrointestinal disease, but focus on different mechanisms—Article A on glycocalyx loss in protein-losing enteropathy while Article B on GLP-2's role in intestinal adaptation for short bowel syndrome.
Parallel
The sepsis-permeability feedback loop
Both articles address intestinal barrier function and integrity in disease states, but Article A focuses on the pathogenic cycle of leaky gut in sepsis while Article B focuses on therapeutic restoration of intestinal function through GLP-2 in short bowel syndrome.
Parallel
Ileocecal vulnerability
Both articles address small intestinal dysfunction through different mechanisms—Article A focuses on ileocecal valve dysfunction in SIBO pathophysiology while Article B explores GLP-2 as a therapeutic agent for intestinal adaptation—but lack direct causal or evidential relationship.
Parallel
The vagus nerve and the cholinergic anti-inflammatory pathway
Both articles address therapeutic approaches to intestinal dysfunction through different biological pathways—Article A via vagal anti-inflammatory signaling and Article B via GLP-2-mediated intestinal adaptation—without direct mechanistic overlap or evidence that one builds upon the other.
Published 2026-05-28 · Last kit-update 2026-05-28